UK markets open in 1 hour 5 minutes

Tenaya Therapeutics, Inc. (TNYA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.4200+0.2400 (+5.74%)
At close: 04:00PM EDT
4.3400 -0.08 (-1.81%)
After hours: 05:25PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.1800
Open4.1300
Bid4.4000 x 100
Ask4.4400 x 200
Day's range4.1300 - 4.4700
52-week range1.6600 - 8.0910
Volume328,959
Avg. volume436,590
Market cap347.047M
Beta (5Y monthly)2.62
PE ratio (TTM)N/A
EPS (TTM)-1.6500
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est19.29
  • GlobeNewswire

    Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

    Initial Data from Ongoing MyPEAK™-1 Phase 1b of TN-201 Expected in Second Half of 2024 Clinical Sites Activated for RIDGE™-1 Phase 1b Clinical Trial of TN-401 Announced Cost Containment Measures in Alignment with Focus on Generating Data from Clinical-Stage Gene Therapy Programs Raised $47 Million Net Proceeds in First Quarter Financing; Current Cash Runway into Second Half of 2025 SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-

  • Insider Monkey

    13 Penny Stocks with Insider Buying in 2024

    In this article, we will take a detailed look at the 13 Penny Stocks with Insider Buying in 2024. If you want to skip our detailed analysis and see the top 5 stocks in this list, click 5 Penny Stocks with Insider Buying in 2024. Insider transactions have always drawn market attention as it’s now a well-known fact […]

  • GlobeNewswire

    Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting

    Abstracts Demonstrate Tenaya’s Continued Innovation Across Core Competencies Facilitating Current Pipeline and Enabling Next Wave of Precision Heart MedicinesSOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it will present seven abstracts focused on the